DE69329887D1 - Thienobenzodiazepinderivate zur Behandlung von Störungen des Zentralnervensystems - Google Patents

Thienobenzodiazepinderivate zur Behandlung von Störungen des Zentralnervensystems

Info

Publication number
DE69329887D1
DE69329887D1 DE69329887T DE69329887T DE69329887D1 DE 69329887 D1 DE69329887 D1 DE 69329887D1 DE 69329887 T DE69329887 T DE 69329887T DE 69329887 T DE69329887 T DE 69329887T DE 69329887 D1 DE69329887 D1 DE 69329887D1
Authority
DE
Germany
Prior art keywords
disorders
treatment
nervous system
central nervous
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69329887T
Other languages
English (en)
Other versions
DE69329887T2 (de
Inventor
John Fairhurst
Terrence Michael Hotten
David Edward Tupper
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co Ltd
Eli Lilly and Co
Original Assignee
Eli Lilly and Co Ltd
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB929211379A external-priority patent/GB9211379D0/en
Priority claimed from GB939309025A external-priority patent/GB9309025D0/en
Application filed by Eli Lilly and Co Ltd, Eli Lilly and Co filed Critical Eli Lilly and Co Ltd
Publication of DE69329887D1 publication Critical patent/DE69329887D1/de
Application granted granted Critical
Publication of DE69329887T2 publication Critical patent/DE69329887T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Addiction (AREA)
  • Anesthesiology (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
DE69329887T 1992-05-29 1993-05-26 Thienobenzodiazepinderivate zur Behandlung von Störungen des Zentralnervensystems Expired - Fee Related DE69329887T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB929211379A GB9211379D0 (en) 1992-05-29 1992-05-29 Pharmaceutical compounds
GB939309025A GB9309025D0 (en) 1993-04-30 1993-04-30 Pharmaceutical compounds

Publications (2)

Publication Number Publication Date
DE69329887D1 true DE69329887D1 (de) 2001-03-01
DE69329887T2 DE69329887T2 (de) 2001-05-23

Family

ID=26300951

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69329887T Expired - Fee Related DE69329887T2 (de) 1992-05-29 1993-05-26 Thienobenzodiazepinderivate zur Behandlung von Störungen des Zentralnervensystems

Country Status (21)

Country Link
EP (1) EP0582368B1 (de)
JP (1) JP3219541B2 (de)
CN (1) CN1043994C (de)
AT (1) ATE198891T1 (de)
AU (1) AU668159B2 (de)
CA (1) CA2097016A1 (de)
CZ (1) CZ282783B6 (de)
DE (1) DE69329887T2 (de)
DK (1) DK0582368T3 (de)
ES (1) ES2153373T3 (de)
FI (1) FI101538B (de)
GR (1) GR3035587T3 (de)
HU (1) HU218278B (de)
IL (1) IL105827A (de)
MX (1) MX9303124A (de)
MY (1) MY109943A (de)
NO (1) NO305125B1 (de)
NZ (1) NZ247703A (de)
PT (1) PT582368E (de)
RU (1) RU2125574C1 (de)
TW (1) TW268005B (de)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5457101A (en) * 1994-06-03 1995-10-10 Eli Lilly And Company Thieno[1,5]benzoidiazepine use
US5574028A (en) * 1994-10-31 1996-11-12 Eli Lilly And Company Method for treating anxiety
EG24221A (en) * 1995-03-24 2008-11-10 Lilly Co Eli Process for preparing olanzapine
CR5278A (es) 1995-03-24 1996-07-04 Lilly Co Eli Formulacion oral de 2-metil-tieno-benzodiacepina
EG23659A (en) * 1995-03-24 2007-03-26 Lilly Co Eli Process and crystal forms of methyl-thieno-benzodiazepine
US5891461A (en) * 1995-09-14 1999-04-06 Cygnus, Inc. Transdermal administration of olanzapine
IL126063A (en) * 1996-03-25 2002-04-21 Lilly Co Eli Medicinal products containing ulanzapine for the treatment of migraine pain
CN1494907A (zh) * 1996-03-25 2004-05-12 治疗疼痛的药物组合物
CN1219878A (zh) * 1996-03-25 1999-06-16 伊莱利利公司 治疗疼痛的方法
ZA978515B (en) * 1996-09-23 1999-03-23 Lilly Co Eli Intermediates and process for preparing olanzapine
AU720366B2 (en) 1996-09-23 2000-06-01 Eli Lilly And Company Olanzapine dihydrate D
ID21762A (id) * 1996-09-24 1999-07-22 Lilly Co Eli Formulasi partikel bersaput
US20140057303A1 (en) 2012-08-21 2014-02-27 Janssen Pharmaceutica Nv Antibodies to Olanzapine Haptens and Use Thereof
EP3556759B1 (de) 2012-08-21 2023-11-29 Janssen Pharmaceutica NV Haptene von paliperidon
WO2014031665A1 (en) 2012-08-21 2014-02-27 Ortho-Clinical Diagnostics, Inc Antibodies to quetiapine haptens and use thereof
JP6374387B2 (ja) 2012-08-21 2018-08-15 ヤンセン ファーマシューティカ エヌ．ベー． リスペリドンハプテンへの抗体及びその使用
CA2882615C (en) 2012-08-21 2019-07-09 Ortho-Clinical Diagnostics, Inc. Antibodies to quetiapine and use thereof
CN104755479B (zh) 2012-08-21 2016-11-09 詹森药业有限公司 利培酮和帕潘立酮的半抗原
JP2015529199A (ja) 2012-08-21 2015-10-05 オルソ−クリニカル ダイアグノスティクス，インコーポレイティド パリペリドンハプテンに対する抗体及びその使用
JP6131415B2 (ja) 2012-08-21 2017-05-24 ヤンセン ファーマシューティカ エヌ．ベー． イムノアッセイに使用するためのクエチアピンのハプテン
CN104736567B (zh) 2012-08-21 2019-09-03 詹森药业有限公司 阿立哌唑半抗原的抗体及其用途
PT2888269T (pt) * 2012-08-21 2019-01-17 Janssen Pharmaceutica Nv Haptenos de olanzapina
PT2888234T (pt) 2012-08-21 2018-02-22 Janssen Pharmaceutica Nv Haptenos de aripiprazol e seu uso em imunoensaios
CA2882490A1 (en) 2012-08-21 2014-02-27 Ortho-Clinical Diagnostics, Inc. Antibodies to paliperidone and use thereof
TR201816416T4 (tr) 2012-08-21 2018-11-21 Janssen Pharmaceutica Nv Risperidona yönelik antikorlar ve bunların kullanımı.
ES2762105T3 (es) 2012-08-21 2020-05-22 Janssen Pharmaceutica Nv Anticuerpos para aripiprazol y uso de los mismos
CN104755928B (zh) 2012-08-21 2017-05-10 詹森药业有限公司 奥氮平的抗体及其用途
WO2017106508A1 (en) 2015-12-17 2017-06-22 Janssen Pharmaceutica Nv Antibodies to quetiapine and use thereof
CA3008809A1 (en) 2015-12-17 2017-06-22 Janssen Pharmaceutica Nv Antibodies to risperidone and use thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU629879A3 (ru) * 1974-11-26 1978-10-25 Лилли Индастриз Лимитед, (Фирма) Способ получени тиено(1,5) бензодиазепинов или их солей
FI762646A (de) * 1975-09-24 1977-03-25 Sandoz Ag
GB9009229D0 (en) * 1990-04-25 1990-06-20 Lilly Industries Ltd Pharmaceutical compounds

Also Published As

Publication number Publication date
HUT66180A (en) 1994-09-28
NO305125B1 (no) 1999-04-06
NZ247703A (en) 1995-07-26
NO931917L (no) 1993-11-30
RU2125574C1 (ru) 1999-01-27
GR3035587T3 (en) 2001-06-29
FI932445A (fi) 1993-11-30
AU668159B2 (en) 1996-04-26
HU218278B (en) 2000-07-28
FI101538B1 (fi) 1998-07-15
CN1043994C (zh) 1999-07-07
EP0582368A1 (de) 1994-02-09
IL105827A (en) 1997-02-18
IL105827A0 (en) 1993-09-22
PT582368E (pt) 2001-05-31
NO931917D0 (no) 1993-05-26
CZ282783B6 (cs) 1997-10-15
HU9301579D0 (en) 1993-09-28
CZ102493A3 (en) 1993-12-15
FI101538B (fi) 1998-07-15
MY109943A (en) 1997-10-31
DE69329887T2 (de) 2001-05-23
EP0582368B1 (de) 2001-01-24
JPH0687862A (ja) 1994-03-29
MX9303124A (es) 1993-11-01
TW268005B (de) 1996-01-11
ES2153373T3 (es) 2001-03-01
FI932445A0 (fi) 1993-05-28
ATE198891T1 (de) 2001-02-15
AU3980793A (en) 1993-12-02
JP3219541B2 (ja) 2001-10-15
CN1085903A (zh) 1994-04-27
DK0582368T3 (da) 2001-02-05
CA2097016A1 (en) 1993-11-30

Similar Documents

Publication Publication Date Title
DE69329887T2 (de) Thienobenzodiazepinderivate zur Behandlung von Störungen des Zentralnervensystems
IE893246L (en) Biologically active compounds
ES2164718T3 (es) Compuestos triciclicos de amida y urea utiles para inhibir la funcion de la proteina-g y para el tratamiento de enfermedades proliferativas.
MX9200015A (es) Derivados de amida y proceso para su preparacion.
DE69411424T2 (de) Zur Behandlung von Erkrankungen des Zentralnervensystems verwendbare Benzimidazole
DE3684190D1 (de) Verwendung von tetrahydrobiopterinen zur herstellung eines medikaments zur behandlung von kinderautismus.
NO1998008I1 (no) Naratriptan
ATE206919T1 (de) Verwendung des wirkstoffs flupirtin zur herstellung eines arzneimittels zur bekämpfung von muskelverspannungen
FI893751A0 (fi) Kemiska foereningar.
ATE88894T1 (de) Methode zur behandlung von kachexie und bestimmte dafuer anzuwendende verbindungen.
ATE268337T1 (de) C11-carbamate von antibakteriellen makroliden
MD1560G2 (ro) Compuşi ciclici, compoziţii farmaceutice pe baza lor şi metode de tratament al infecţiilor sau bolilor provocate de retrovirusuri
MA21902A1 (fr) Procede pour la preparation de peptitides hemoregulateurs et des compositions pharmaceutiques les comtenant .
TNSN92017A1 (fr) Procede de preparation, d'un derive de benzothiazole, et d'une composition pharmaceutique le contenant et procede de traitement en comportant application
ATE136896T1 (de) Piperidylmethyl substituierte chromanderivate als wirkstoffe zur behandlung von erkrankungen des zentralnervensystems
EA199700287A1 (ru) Бензамиды для лечения нейродегенеративных заболеваний
DE69327077T2 (de) Carbamoylpyrrolidon-Derivate zur Behandlung von Depressionen und cerebrovasculären Störungen
ATE283269T1 (de) 5-(heteroaryl)alkyl)-3-oxo-pyrido(1,2- a)benzimidazol-4-carboxamid (pbi) derivate zur behandlung von störungen des zentralen nervensystems
ES2097188T3 (es) Derivados organosilanos, composiciones farmaceuticas que los contienen y procedimiento para su preparacion.
ATE242766T1 (de) Neue derivate von benzoylalkyl-1,2,3,6- tetrahydropyridinen

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee